MDS: Current Thinking on the Disease, Diagnosis, and Treatment
Dr. Steensma in this session speaks about MDS and the current thinking on the disease, diagnosis, and treatment this information was presented on September ...
AAMDSIF
Quality of Life as Treatment Goal in MDS
Clinical outcomes and quality of life in patients with MPN and MDS continue to be enhanced as cytogenetic analysis and novel therapeutic strategies are ...
ImedexCME
My approach to MDS management
In this presentation from the 2017 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Rami Komrokji discusses his approach to the ...
ImedexCME
Understanding Myelodysplastic Syndromes (MDS)
Benjamin L. Ebert, MD, Brigham and Women's Hospital, Harvard Medical School Recent discoveries have yielded profound insights into the genetic basis of ...
Society for Translational Oncology
Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (High-Risk MDS)
Dr. Guillermo Garcia-Manero of The University of Texas MD Anderson Cancer Center, Houston, TX discusses the overall survival and subgroup analysis from a ...
Oncology.TV
Novel Strategies to Prevent Relapse after Allogeneic Transplantation for MDS
Clinical outcomes and quality of life in patients with MPN and MDS continue to be enhanced as cytogenetic analysis and novel therapeutic strategies are ...
ImedexCME
Patient Selection Considerations With Iron Chelation Therapy in MDS
Panelists Jamile Shammo, MD; Vinod Pullarkat, MD; Ellen K. Ritchie, MD; Thomas Prebet, MD, PhD; and Rami S. Komrokji, MD, outline their clinical experience ...
OncLiveTV
Classification and Prognosis in MDS
James M. Foran, MD, FRCP, and Azra Raza, MD, explain how MDS is classified, and how understanding, with regard to the diagnosis and prognosis of the ...
OncLiveTV
What are the treatment options for MDS?
To learn more visit http://www.YouAndMDS.com MDS experts, Dr Alan List and Dr David Sallman, describe the common treatment options for myelodysplastic ...
You and MDS
Progress and Promise in the Treatment of MDS
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, conclude with the progress and promise in the treatment of myelodysplastic syndrome.
OncLiveTV
Treating Patients with Higher Risk MDS
This webinar will use a combination of lecture and case studies to present the most current thinking on the treatment of higher-risk MDS. It will begin with a short ...
AAMDSIF
Prognosis in Myelodysplastic syndromes - using the IPSS (Advanced)
For more videos by Vernon Louw MedEd, go to: http://www.youtube.com/user/Legomed/videos?view_as=public The International Prognostic Scoring System ...
Vernon Louw MedEd
MPN Transformation to MDS and AML: Risk factors, therapy and outcomes
Filmed on location in Zagreb, Croatia during the European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes from 24-26 April 2015, this ...
ImedexCME
Iron chelation therapy for MDS
In this presentation from the 2017 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Amer Zeidan discusses the use of iron ...
ImedexCME
Stem Cell Transplant Approaches to MDS
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA, Dr.
ImedexCME
Prognosis and treatment in high-risk MDS
Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, discusses the unmet need for novel treatments in high-risk ...
VJHemOnc – Video Journal of Hematological Oncology
ASH 2013 - Andrew Artz on Allogeneic Transplant for High Risk Myelodysplastic Syndromes and AML
From ASH 2013, Andrew Artz, M.D., M.S., discusses his educational session on Allogeneic Transplant for High Risk Myelodysplastic Syndromes and Acute ...
Oncology.TV
New salvage treatment for AML/MDS after allogeneic transplant: the VIOLA trial
The outcome for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after allogeneic stem cell transplantation remains poor. In this ...
VJHemOnc – Video Journal of Hematological Oncology
MPN Transformation to MDS and AML: Risk Factors, Therapy, and Outcomes
As recent discoveries have the potential to change the paradigm of how MPN and MDS are diagnosed and treated, it is imperative that healthcare professionals ...
ImedexCME
Emerging Approaches in MDS Treatment
Panelists Mikkael A. Sekeres, MD, MS; Rami S. Komrokji, MD; Ellen K. Ritchie, MD; and Jamile Shammo, MD, highlight the mechanism of action and current ...
OncLiveTV
MDS: The Good, The Bad, and The Ugly
During this webinar, Dr. Michaelis will focus on helping you understand new and emerging diagnostic procedures and prognostic models and how these tools ...
AAMDSIF
Understanding Myelodysplastic Syndromes (MDS)
Benjamin L. Ebert, MD Recent discoveries have yielded profound insights into the genetic basis of myelodysplastic syndromes and other myeloid malignancies.
The Society for Translational Oncology
Chronic Myelomonocytic Leukemia
Dr. Mrinal Patnaik, a Consultant from the Division of Hematology at Mayo Clinic in Rochester, MN, provides a state-of-the-art update in the February 2016 issue ...
Mayo Proceedings
Treatment Decision-Making through the Spectrum of MDS
MDS (myelodysplastic syndromes) is a heterogeneous group of malignant hematopoietic stem cell disorders that are characterized by dysplastic and ineffective ...
AAMDSIF
The Role of Iron Chelation Therapy in Patients with MDS
Panelists James M. Foran, MD, FRCPC and Azra Raza, MD, look into the role of iron chelation therapy for MDS patients.
OncLiveTV
What is the optimum treatment strategy for high-risk myelodysplastic syndrome?
During the 1st NCRI AML academy meeting, the AML Global Portal was pleased to speak to Professor David Bowen from Leeds Teaching Hospitals, Leeds, UK ...
AML Hub
Myelodysplastic Syndrome | Dr. Tony Talebi discusses "Treatment of Myelodysplastic Syndrome?"
Dr. Tony Talebi discusses "What is the Treatment of Myelodysplastic Syndrome?" with Dr. Byrnes. For further discussion visit http://www.HemOnc101.com What ...
Tony
When HMA Fails: Newer therapeutic agents for MDS
Clinical outcomes and quality of life in patients with MPN and MDS continue to be enhanced as cytogenetic analysis and novel therapeutic strategies are ...
ImedexCME
What is the current treatment approach for secondary MDS?
Dr. Larson discusses the challenges associated with treating secondary MDS, and the therapeutic strategies that have demonstrated efficacy in these patients.
MediCom Oncology
Rationale for Combination Therapy in MDS
Panelists Mikkael A. Sekeres, MD, MS; Jamile Shammo, MD; and Rami S. Komrokji, MD, discuss the rationale for combination therapy in myelodysplastic ...
OncLiveTV
The WHO Updated Diagnostic Criteria for MPN
Clinical outcomes and quality of life in patients with MPN and MDS continue to be enhanced as cytogenetic analysis and novel therapeutic strategies are ...
ImedexCME
Dr. Uberti on Transplant in Myelodysplastic Syndrome
Joseph Uberti, MD, PhD, division head, BMT, Leukemia & Lymphoma, professor of medicine, Department of Oncology, Barbara Ann Karmanos Cancer Institute, ...
OncLiveTV
Hypomethylating Agents in MDS: Factors to Consider
Panelists Mikkael A. Sekeres, MD, MS; Ellen K. Ritchie, MD; Rami S. Komrokji, MD; and Jamile Shammo, MD, outline the patient selection criteria and goals of ...
OncLiveTV
Diagnosis and Therapy of CMML in 2015
Filmed on location in Zagreb, Croatia during the European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes from 24-26 April 2015, this ...
ImedexCME
Treating Lower Risk MDS in 2012
During this webinar the Dr. Steensma will use a combination of lecture and case studies to review the most current thinking on the treatment of lower-risk MDS.
AAMDSIF
Iron chelation therapy in MDS
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, gives his highlights on research for ...
VJHemOnc – Video Journal of Hematological Oncology
When and How to Use Iron Chelation Therapy in MDS
Filmed on location in Zagreb, Croatia during the European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes from 24-26 April 2015, this ...
ImedexCME
Pathobiology of Acute Myeloid Leukemias (AML)
The panelists, Ruben A. Mesa, MD, FACP; Rami Komrokji, MD; Rafael Bejar, MD, PhD; and Elias Jabbour, MD, explain the genetic alterations and ...
OncLiveTV
Dr. Esther Oliva: Azacitidine As Post-Remission Therapy in Elderly Patients with AML
ASH 2014 – Dr. Esther Oliva discusses interim results on a Phase III, prospective, randomized, open-label, multicenter trial is designed to assess the efficacy of ...
Oncology.TV
Erythropoiesis Stimulating Agents and other Growth Factors in Low-risk MDS: An update
Clinical outcomes and quality of life in patients with MPN and MDS continue to be enhanced as cytogenetic analysis and novel therapeutic strategies are ...
ImedexCME
Unmet Needs and Future Directions in Treating MPNs
Expert panelists Harry P. Erba, MD, PhD; Srdan Verstovsek, MD, PhD; Ruben A. Mesa, MD, FACP; Rami Komrokji, MD; and Jamile M. Shammo, MD, FASCP, ...
OncLiveTV
MDS - Approach to Therapy (part 2 of 7)
Three physicians (Dr. Mikkael Sekeres, Dr. Hetty Carraway, and Dr. David Steensma) with extensive experience treating patients with myelodysplastic ...
AAMDSIF
